ArticleCurrent therapeutic research, clinical and experimental2026
Investigation of the correlation between serum levels of interleukin-6 and clinical and paraclinical findings in COVID-19 patients.
Article in Current therapeutic research, clinical and experimental, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: COVID-19 frequently presents with pneumonia. Impaired immune function, particularly in older adults and immunocompromised individuals, increases susceptibility to infection and contributes to higher morbidity and mortality. Among inflammatory cytokines, Interleukin-6 (IL-6) plays a pivotal role in immune dysregulation and cytokine storm. Therefore, this study aimed to investigate the association between serum IL-6 levels and clinical, laboratory, radiological, and outcome-related findings among hospitalized patients with COVID-19. Methods: This descriptive-analytical cross-sectional study included 210 hospitalized COVID-19 patients at Shahid Beheshti Hospital, Kashan. Serum IL-6 was measured as part of their diagnostic and therapeutic workup. Demographic characteristics, clinical manifestations, laboratory markers, imaging findings, and outcomes were recorded. Patients with incomplete data were excluded. Data were analyzed using SPSS software version 26. Results: The mean age of patients was 50.37 ± 17.48 years, with a slight male predominance (51%). Hypertension was the most common comorbidity (31.9%). Abnormal laboratory markers included elevated LDH (64.3%), ESR (61.0%), lymphopenia (59.5%), and CRP (58.6%). Pulmonary involvement on CT was noted in 91.5% of patients, with moderate involvement most frequent (41.4%). ICU admission occurred in 17.1% and mechanical ventilation was required in 10.5%. The mean CALL score was 8.63 ± 2.33, and average hospital stay was 6.70 ± 5.27 days. Serum IL-6 levels were significantly associated ( Conclusion: Elevated serum IL-6 strongly reflects disease severity and adverse outcomes in COVID-19, highlighting its potential as a prognostic biomarker to guide clinical assessment and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.